Bayesian interval dose-finding designs: Methodology and Application
|
|
- Alexandra McDaniel
- 6 years ago
- Views:
Transcription
1 Bayesian interval dose-finding designs: Methodology and Application May 29, 2018
2 Conflict of Interests The U-Design webtool is developed and hosted by Laiya Consulting, Inc., a statistical consulting firm co-founded by Yuan Ji.
3 Contents 1. Standard and new dose-finding designs 2. Interval-based designs for dose finding 3. Application via the U-Design Webtool
4 Standard and new dose-finding designs
5 Consider trials with fixed doses. Phase I dose-finding (Oncology) Setup Climb up and down a sequence of D ordered doses of a new drug to determine the maximum tolerated dose (MTD). Data At each dose i, n i patients are tested, y i patients experienced toxicity outcome (DLT). Parameters Dose i has a toxicity probability of p i (unknown). Sampling Model Binomial y i p i Bin(n i, p i ) Assumption Toxicity Monotonicity : p i p i+1. Hidden assumption Efficacy Monotonicity : q i q i+1 if not, why escalate when the dose is safe? Goal to find the MTD, defined as the highest dose with toxicity rate lower (or close to) a target rate, p T, e.g., p T = 0.30.
6 A hypothetical dose-finding trial
7 A hypothetical dose-finding trial
8 A hypothetical dose-finding trial
9 A hypothetical dose-finding trial
10 A hypothetical dose-finding trial
11 A hypothetical dose-finding trial
12 A hypothetical dose-finding trial
13 A hypothetical dose-finding trial
14 A hypothetical dose-finding trial
15 A hypothetical dose-finding trial
16 A hypothetical dose-finding trial
17 A hypothetical dose-finding trial
18 A hypothetical dose-finding trial
19 Existing Designs 3+3 Storer (1989). Algorithmic design; simple and transparent Insufficient power to find the MTD even with sufficient resources Contradicting rules : Stay for 1/3; Escalate for 1/6 (MTD not exceeded)
20 Existing Designs 3+3 Storer (1989). Algorithmic design; simple and transparent Insufficient power to find the MTD even with sufficient resources Contradicting rules : Stay for 1/3; Escalate for 1/6 (MTD not exceeded) CRM The first model-based design. First publication in Performs well but could be sensitive to prior models; black-box to physicians mtpi and mtpi-2 Model-based interval designs in an algorithmic presentation (Ji et al., 2010; Guo et al., 2017). Optimal under a formal Bayesian decision framework CCD and BOIN Cumulative cohort design (CCD, Ivanova et al. 2007) a Markov process and a simple rule BOIN (Liu and Ying) is an extension of CCD Their inference is based on point estimates (not accounting for variabilities) of toxicity probabilities; BOIN s asymptotic behavior is strange
21 The Industry-Standard 3+3 Design Yang, Wang, and Ji (2015) An integrated dose-finding tool for phase I trials in oncology.
22 The 3+3 Design: should be a past history? Features Simple; Transparent; FDA review reward for being inferior and naive Problems Target highest dose with no more than 1/6 DLT rate; but STAY when 1 out 3 patients has DLT Cannot target p T values different from 1/6 Cannot have large power (3+3 treats no more than 6 patients per dose) what if one has more resources to spend?
23 The 3+3 Design: it should be a past history Ji and Wang (2013, JCO) showed that with matched sample size, 3+3 is less safe and reliable when compared to the mtpi design, a model-based design. The 2015 FDA/AACR Dose-Finding Symposium concluded that (Nie et al., 2016, Clinical Cancer Research) The MTD/3+3 approach is not optimal and may result in recommended doses that are unacceptably toxic for many patients and in dose reduction/interruptions that might have an impact on effectiveness.
24 The CRM Design a specific model Perhaps the most popular version of the CRM is the power model: The dose-response curve : p i = p exp(α) i0, where p i0 are fixed and prespecified constants, and α is a parameter that describes the dose response curve. The prior for α is N(0, 2). The p i0 s are decided by solving E[p exp(α) i ] = s i, where s i s are a set of prior probabilities that one must determine (called skeletons ). A binomial likelihood: d i=1 pyi i (1 p i) ni yi. Posterior of α is obtained by numerical integration. The next dose is arg min i ˆp i p T, where ˆp i is the posterior mean.
25 The CRM Design trial conduct and decision tables Challenging to implement in practice (logistic and effort support) Coherence (some version is NOT coherence ) and Over-dose control (e.g., no skipping dose when escalation) Team meetings are needed for every patient allocation CRM decisions may be overruled Output CRM Decision Tables for assessment (U-Design Platform (udesign.laiyaconsulting.com))
26 Interval Designs
27 Hallmark of Interval Designs The decision of dose finding is based on toxicity probability intervals. Interval designs : up-and-down decisions based on intervals (mtpi, mtpi-2, CCD, BOIN) Stay Escalate De-escalate p i (p T ɛ 1, p T + ɛ 2 ) p i (0, p T ɛ 1 ) p i (p T + ɛ 2, 1) Non-interval designs : CRM chooses the dose arg min i ˆp i p T, 3+3 uses up-and-down decisions based on y i n i,
28 Interval-Based Decision Setting Given the target toxicity probability p T (e.g., p T = 0.16 or 0.3), and effect size ɛ 1, ɛ 2, the interval-based decision is based on the following framework. Idea Divide (0, 1) into three intervals: (0, p T ɛ 1 ) }{{} Under dosing interval (p T ɛ 1, p T + ɛ 2 ) }{{} Equivalence Interval (p T + ɛ 2, 1) }{{} Under dosing interval [Associate with actions] E, S, D Decision rule Use Bayes rule to decide which action (decision) to take for the next patient. Next: Let us use mtpi and mtpi-2 as examples.
29 Decision Theory 101 Data Y is used to define likelihood function p(y θ). Dose finding : p(y θ) i pyi i (1 p i) ni yi. Parameters are quantities of interests. Dose finding : θ = {p 1,, p D }; Prior p(θ η)p(η) (η are additional parameters) Actions a to be taken (e.g., estimators). Dose finding : a {D, S, E} Optimal Decision Making is based on the following steps: Loss (Utility) function Define loss l(a, θ) as a function of a and θ Optimality criterion define what you want to optimize. For Bayesian, maximize posterior expected loss : l(a, θ)p(θ Y)dθ Optimal decision rule determines the action that achieves the optimality criterion. For Bayesian, we use Bayes Rule a = arg min l(a, θ)p(θ Y)dθ a
30 The mtpi and mtpi-2 Designs Use Bayes Rule Consider mtpi for now. Data Y mtpi : p(y θ) i pyi i (1 p i) ni yi. Parameter θ Tox probs {p i } = {p 1,, p D }; In addition to {p i }, introduce another parameter m i {M D, M S, M E } and Then mtpi : θ = {p i } {m i } Actions a mtpi : a {D, S, E}. Loss function mtpi : l(a = i, m i = M j ) = M D : p i (p T + ɛ 2, 1) M S : p i (p T ɛ 1, p T + ɛ 2 ) M E : p i (0, p T ɛ 1 ) { 1, if i j; 0, if i = j, for i, j {E, S, D}. Optimal decision mtpi uses Bayes rule : For dose i, choose decision a (p T, ɛ 1, ɛ 2 ) = arg max P r(m i = M j Y) j {D,S,E}
31 The mtpi Design Given p T, ɛ 1, ɛ 2, all the decisions a are pre-calculated for all the possible data Y at dose i. An mtpi decision table but in an algorithmic form
32 UPM and Bayes rule If we assume a simple working model (Ji et al., 2010), y i p i Binom(n i, p i ), and p i indep Beta(1, 1) then the working posterior is q(p i y) = Beta(1 + y i, 1 + n i y i ) Turns out the mtpi s rule to max P r(m i = M j Y) is the equivalent tomax the unit probability mass under the working posterior. P r(m i = M j Y) = UPM(M j ) = q(p i M j Y), j {D, S, E} length(m j)
33 Ockham s razor and mtpi In mtpi, when 3 out of 6 patients have DLT and if p T = 0.3, the decision based on UPM is S, to stay at the current dose. Why? Ockham s razor states the principle that an explanation of the facts should be no more complicated than necessary Bayesian model selection requires a prior p(m k ) for the candidate model k and a prior p(θ k M k ). Models are selected based on p(m k data) and automatically applies the Ockham s razor: when two models fit the data equally well, the smaller one wins. The mtpi design considers three intervals that partition the sample space (0, 1) for the probability of toxicity p i at a given dose d: M D : p i (p T + ɛ 2, 1) M S : p i (p T ɛ 1, p T + ɛ 2 ) M E : p i (0, p T ɛ 1 ) (1) Typically, p T ranges from 0.1 to 0.3 in phase I trials, and ɛ s are usually small, say So M S the middle interval is the smallest (shortest).
34 Ockham s razor and interval length Con t mtpi uses Bayes rule : For dose i, choose decision a (p T, ɛ 1, ɛ 2 ) = arg max P r(m i = M j Y) j {D,S,E} Given y i = 3 patients with toxicity events out of n i = 6 patients at dose i, mtpi decision is a = S. This is because the posterior probability P r(m i = M s Y) is the largest. See UPMs for three intervals below: UPM(E) UPM(S) 3/6 UPM(S)
35 Ockham s razor is the SOUND statistical inference Optimality The mtpi design uses Bayes rule for decision, which is optimal in the sense that it minimizes the posterior expected loss (maximize the posterior probability of each interval) Ockham s razor favors the equivalence interval [p T ɛ 1, p T + ɛ 2 ] because it is the most parsimonious (shortest) model Stay when p T = 0.3 and y/n = 3/6 is a result of Ockham s razor, which is statistically sound Ethical consideration However, in practice, one may argue that the decision is aggressive. SOLUTION: To blunt the Ockham s razor! The mtpi-2 design purely for the purpose of practical consideration no consensus!
36 The mtpi-2 design (Guo et al., 2017): Blunt the Ockham s Razor Divid (0, 1) into subintervals with equal length, same as that of (p T ɛ 1, p T + ɛ 2 ). Pick the decision {D, S, E} corresponding to the interval with the largest UPM. Still the Bayes (optimal) rule Density of B(3, 3) Post. Density for x d=3, n d=6 UPM's LI M EI HI HI HI... M 1 M 1 M 2 M
37 The mtpi-2 Design Has Fewer S than mtpi
38 The CCD and BOIN designs
39 Cumulative Cohort Design (CCD) Ivanova et al. (2007) proposed a simple interval-based design: Stay Escalate De-escalate y i n i (0, p T ɛ 1 ) y i n i (p T ɛ 1, p T + ɛ 2 ) y i n i (p T + ɛ 2, 1) The decision is based on the point estimate yi n i (MLE, posterior mode under Unif(0,1) prior) not accounting for variabilities The intervals are used as boundaries for thresholding the point estimate yi n i but not directly related to the estimators mtpi calculates posterior probabilities of the intervals accounting for variabilities The up-and-down decision rules generate a Markov chain of decisions, which is shown to converge asymptotically to a desirable stationery distribution (Ivanova et al., 2007) The CCD uses equal ɛ 1 = ɛ 2 values based on a theoretical derivation.
40 The BOIN Design A hybrid between CCD and mtpi. Use the same type of decision rules as CCD (y i /n i interval) Stay Escalate De-escalate y i y n i (p T ɛ 1, p T + ɛ 2 ) i y n i (0, p T ɛ 1 ) i n i (p T + ɛ 2, 1) The ɛ s are derived based on φ 1 and φ 2 values that are below and above p T, provided by users. BOIN uses the same MTD selection and safety rules as in mtpi. BOIN stands for Bayesian optimal interval design. The parameter space has three points: only allow p i taking three values H 0 : p i = p T, H 1 : p i = p T ɛ 1, and H 2 : p i = p T + ɛ 2 The optimality criterion is ad-hoc and not based on a loss function or a formal decision theoretic framework. The optimization in BOIN is trying to mimic a p-value type of calculation So theoretically the BOIN design is based on an ad-hoc framework, not following the classical optimal decision theory. This leads to some asymptotically strange behavior (two slides later).
41 Two Types of Interval-Based Designs The TPI, mtpi, and mtpi-2 designs anchor decision based on P r(p i interval data) and uses a formal decision theoretic framework to find the optimal decision based on the current trial data. The CCD and BOIN designs anchor decision based on y i n i interval and uses the intervals to threshold yi n i. In small sample phase I trials, the distinction might not make a big difference in the frequentist operating characteristics based on a large number of computer simulations. Theoretically, some concerns about the use of point estimate and the specific setup in BOIN.
42 A pictorial summary of mtpi and BOIN BOIN has a gap that is asymptotically inconsistent When sample size n i, the gap still exists. This creates wrong asymptotic decisions. The mtpi (mtpi-2) Design) The BOIN Design Pr(3 & )'*+,-./) )'*+,-./ % & ' & )'*+,-./ Escalate Stay (retain) De-escalate Escalate Stay (retain) De-escalate $ " p T $ # 0 1 Nominal boundary & Decision boundary 0 $ "! " p T! # $ # 1 Decision boundary gap gap Nominal boundary
43 Practical performance of mtpi-2 and BOIN is great Ying et al. (2016) show BOIN performs more favorably when compared to mtpi in terms of safety, for a small set of scenarios mtpi is wounded by the Ockham s razor Guo et al. (2017) show that mtpi-2 is safer than BOIN, and slightly more reliability in finding the true MTD. Ji and Yang (2017) report a comprehensive review.
44 Operating characteristics of various designs We compared mtpi, mtpi-2, 3+3, CRM, BOIN in terms of reliability (power of finding MTD) and safety. mtpi-2 is the top performer, followed by BION. Ji and Yang (2017; )
45 A New Web-based Integrative Statistical Platform
46 A New Web-based Integrative Statistical Platform Web Based: No need to download any software; works on MAC, PC, ipad, and smart phones just need an internet browser (e.g., Chrome, FireFox) Integrative: Offers up to six designs, 3+3, CRM, mtpi-2, BLRM, etc. Many new features: CRM decision table, etc. User-friendly: One-click download of statistical section writeup for protocols
arxiv: v2 [stat.me] 14 Jun 2017
On the Interval-Based Dose-Finding Designs Yuan Ji arxiv:1706.03277v2 [stat.me] 14 Jun 2017 Program for Computational Genomics & Medicine, NorthShore University HealthSystem Department of Public Health
More informationBOIN: A Novel Platform for Designing Early Phase Clinical Tri
BOIN: A Novel Platform for Designing Early Phase Clinical Trials Department of Biostatistics The University of Texas, MD Anderson Cancer Center Outline Introduction Bayesian optimal interval (BOIN) designs
More informationModel-based Designs in Oncology Dose Finding Studies
Cytel Workshop 2015 Model-based Designs in Oncology Dose Finding Studies Ling Wang Overview of Oncology Dose Finding Studies Oncology is a special therapeutic area in which dose finding studies, including
More informationPage 78
A Case Study for Radiation Therapy Dose Finding Utilizing Bayesian Sequential Trial Design Author s Details: (1) Fuyu Song and (2)(3) Shein-Chung Chow 1 Peking University Clinical Research Institute, Peking
More informationSEARS: A Seamless Dose Escalation/Expansion with Adaptive Randomization Scheme
SEARS: A Seamless Dose Escalation/Expansion with Adaptive Randomization Scheme Haitao Pan 1,2, Fang Xie 4, Ping Liu 5, Jielai Xia 1,, Yuan Ji 3, March 7, 2012 1 Department of Health Statistics, Fourth
More information3+3 Consensus Meeting Introducing Model Based Dose Escalation in a Pharmaceutical Environment. James Matcham Head, ECD Biometrics 3 rd December 2014
3+3 Consensus Meeting Introducing Model Based Dose Escalation in a Pharmaceutical Environment James Matcham Head, ECD Biometrics 3 rd December 2014 Agenda Background Challenge Actions Outcome 2 JMatcham
More informationThe BEST Platform. A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018
The BEST Platform A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018 Introduction The Bayesian early-phase seamless transformation (BEST) platform
More informationA likelihood-based approach to selecting doses with acceptable toxicity in a standard phase I algorithm
A likelihood-based approach to selecting doses with acceptable toxicity in a standard phase I algorithm Cody Chiuzan, Elizabeth Garrett-Mayer Department of Public Health Sciences Medical University of
More informationJim Bolognese, Cytel Inc. 05Nov2015
Modified Toxicity Probability Intervals (mtpi), Bayesian Logistic Regression Modeling (BLRM), Continual Reassessment Method (CRM) via EAST6.3.1 vs. T-statistic (Tstat) Design via COMPASS for finding MTD
More informationBayesian Designs for Clinical Trials in Early Drug Development
Vol. 3, No. 6, June 007 Can You Handle the Truth? Bayesian Designs for Clinical Trials in Early Drug Development By St. Clare Chung and Miklos Schulz Introduction A clinical trial is designed to answer
More informationImpact of model complexity on adaptive dose-finding methods
Impact of model complexity on adaptive dose-finding methods Alexia Iasonos, Ph.D. Memorial Sloan Kettering Cancer Center Nolan A. Wages, Ph.D. University of Virginia Outline Objectives of Phase I or early
More informationSingle and Double Agent Oncology Dose-Escalation Designs in East 6.4: A communication tool. Shaping the Future of Drug Development
Shaping the Future of Drug Development Single and Double Agent Oncology Dose-Escalation Designs in East 6.4: A communication tool Pantelis Vlachos, Ph.D. Cytel Inc. Geneva Agenda What s new? Single- Agent
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH PHASE I CLINICAL TRIALS: CONTINUAL REASSESSMENT METHOD (CRM) When designing cancer clinical trials for development and evaluation of therapeutic
More informationBayesian Designs for Early Phase Clinical Trials
Bayesian Designs for Early Phase Clinical Trials Peter F. Thall, PhD Department of Biostatistics M.D. Anderson Cancer Center Fourteenth International Kidney Cancer Symposium Miami, Florida, November 6-7,
More informationAn Adaptive Oncology Dose Finding Trial Using the Time-to-Event Continual Reassessment Method Incorporating Cycle Information
An Adaptive Oncology Dose Finding Trial Using the Time-to-Event Continual Reassessment Method Incorporating Cycle Information Bo Huang, PhD Oncology Business Unit Pfizer Inc. PhRMA KOL Adaptive Design
More informationThree Methods for Phase I/II Clinical Trials, with Application to Allogeneic
Three Methods for Phase I/II Clinical Trials, with Application to Allogeneic Stem Cell Transplantation Peter F. Thall, PhD Biostatistics Department M.D. Anderson Cancer Center Workshop on Clinical Trial
More informationAdaptive Design for Clinical Trials
Adaptive Design for Clinical Trials Mark Chang Millennium Pharmaceuticals, Inc., Cambridge, MA 02139,USA (e-mail: Mark.Chang@Statisticians.org) Abstract. Adaptive design is a trial design that allows modifications
More informationCoherence in early phase dose-finding studies Ken Cheung Dept of Biostatistics Columbia University
Coherence in early phase dose-finding studies Ken Cheung Dept of Biostatistics Columbia University Agenda Motivation Phase I cancer trials The conventional method ( 3+3 ) Literature: review & critique
More informationA Constrained Optimum Adaptive Design for Dose Finding in Early Phase Clinical Trials
A Constrained Optimum Adaptive Design for Finding in Early Phase Clinical Trials Iftakhar Alam Barbara Bogacka Steve Coad School of Mathematical Sciences Queen Mary University of London m.alam@qmul.ac.uk
More informationNon-parametric optimal design in dose finding studies
Biostatistics (2002), 3, 1,pp. 51 56 Printed in Great Britain Non-parametric optimal design in dose finding studies JOHN O QUIGLEY Department of Mathematics, University of California, San Diego, CA 92093,
More informationContinuous Safety Monitoring in Large Phase I Cancer Clinical Trials with Multiple Expansion Cohorts
Continuous Safety Monitoring in Large Phase I Cancer Clinical Trials with Multiple Expansion Cohorts Masha Kocherginsky, PhD 1 Theodore Karrison, PhD 2 1 Northwestern University and 2 The University of
More informationCOMPARISON OF NOVEL PHASE I CLINICAL TRIAL DESIGNS BASED ON TOXICITY PROBABILITY INTERVALS. Yi Yao. MA, Shanghai University of Sports, China, 2012
COMPARISON OF NOVEL PHASE I CLINICAL TRIAL DESIGNS BASED ON TOXICITY PROBABILITY INTERVALS by Yi Yao MA, Shanghai University of Sports, China, 2012 MSW, University of Pittsburgh, 2015 Submitted to the
More informationBayesian Adaptive Designs for Precision Medicine: Promise, Progress, and Challenge. J. Jack Lee, Ph.D. Professor, Department of Biostatistics
Bayesian Adaptive Designs for Precision Medicine: Promise, Progress, and Challenge J. Jack Lee, Ph.D. Professor, Department of Biostatistics Nothing to disclose. Disclosure How Do We Bring Theory to Practice
More informationContinual Reassessment Method for First-in-Human Trial: From Design to Trial Implementation
Continual Reassessment Method for First-in-Human Trial: From Design to Trial Implementation Inna Perevozskaya Statistical Research and Consulting Center, Pfizer in collaboration with Lixin Han, Infinity
More informationBayesian Approaches to Phase I Clinical Trials:
Bayesian Approaches to Phase I Clinical Trials: Methodological and Practical Aspects Design of Experiments in Healthcare Isaac Newton Institue of Mathematical Sciences August 2011, Cambridge UK Beat Neuenschwander
More informationEffTox Users Guide and Tutorial (version 2.9)
EffTox Users Guide and Tutorial (version 2.9) Introduction This program is a (beta) implementation of the dose-finding method described in "Dose- Finding Based on Efficacy-Toxicity Trade-Offs" by Peter
More informationImproving Safety of the Continual Reassessment Method via a Modified Allocation Rule
arxiv:1807.05781v1 [stat.me] 16 Jul 2018 Improving Safety of the Continual Reassessment Method via a Modified Allocation Rule Pavel Mozgunov and Thomas Jaki Department of Mathematics and Statistics, Lancaster
More informationA toxicity-dependent feasibility bound for the Escalation with Overdose Control approach in phase I cancer trials
A toxicity-dependent feasibility bound for the Escalation with Overdose Control approach in phase I cancer trials Graham Wheeler 1,2 Michael Sweeting 3 Adrian Mander 2 1 Cancer Research UK & UCL Cancer
More informationCancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents arxiv:1709.00918v3 [stat.me] 22 Aug 2018 José L. Jiménez 1, Mourad
More informationOptimizing Phase 1 and 2 Clinical Trials Design. Stephanie Green and Tao Wang
Optimizing Phase 1 and 2 Clinical Trials Design Stephanie Green and Tao Wang 1 Phase 1 options OUTLINE Improve efficiency over 3+3 Use other designs if standard assumptions are not met Phase 1 2 strategy
More informationEstablish the Maximum Tolerated Dose in Phase-I Trials using 3+3 Method
Establish the Maximum Tolerated Dose in Phase-I Trials using 3+3 Method Anup Pillai Cytel, Pune, India Vienna 11 th - 14 th October 2015 1 Agenda Ø Introduction to Phase-1 trials Ø Dose Escalation Studies
More informationPRACTICAL EXTENSIONS OF THE CONTINUAL REASSESSMENT METHOD AMBER R. SALTER
PRACTICAL EXTENSIONS OF THE CONTINUAL REASSESSMENT METHOD by AMBER R. SALTER INMACULADA B. ABAN, CHAIR GARY CUTTER CHARITY MORGAN JOHN O QUIGLEY JOHN RINKER A DISSERTATION Submitted to the graduate faculty
More informationOncology New Drug Development. Tomoyuki Kakizume Novartis Pharma K.K. Oncology Biometrics and Data Management Dept.
Novartis: Challenging to Accelerate Oncology New Drug Development Tomoyuki Kakizume Novartis Pharma K.K. Oncology Biometrics and Data Management Dept. Bayesian Clinical Trials in Novartis Oncology Phase
More informationA Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities
Bayesian Analysis (2013) 8, Number 3, pp. 703 722 A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities Suyu Liu and Jing Ning Abstract. We propose a Bayesian adaptive dose-finding
More informationA robust Bayesian dose-finding design for phase I/II clinical trials
Biostatistics (2016), 17,2,pp. 249 263 doi:10.1093/biostatistics/kxv040 Advance Access publication on October 20, 2015 A robust Bayesian dose-finding design for phase I/II clinical trials SUYU LIU Department
More informationA Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
Biometrics 65, 866 875 September 2009 DOI: 10.1111/j.1541-0420.2008.01119.x A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents Guosheng Yin and Ying Yuan Department of Biostatistics,
More informationThe Promise of Novel Clinical Trial Designs. Michael Parides, Ph.D. Mount Sinai School of Medicine
The Promise of Novel Clinical Trial Designs Michael Parides, Ph.D. Mount Sinai School of Medicine Productivity New Drug Approvals (NMEs) R&D Spending (billions) $12 $13 $13 $15 $49 $38 $39 $43 $30 $32
More informationBayesian modelling for combination dose-escalation trial that incorporates pharmacokinetic data
Bayesian modelling for combination dose-escalation trial that incorporates pharmacokinetic data Daniel Lorand (Oncology Early Clinical Biostatistics, Novartis) Basel Biometrics Society Seminar - April
More informationDose Finding & Strategies for Novel Combination Development
Dose Finding & Strategies for Novel Combination Development Drug Development Paradigm in Oncology NAM NCPF & Forum on Drug Discovery 12-13 December 2016 Steven Piantadosi, M.D., Ph.D. Phase One Foundation
More informationBayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
Biometrics 62, 777 787 September 2006 DOI: 10.1111/.1541-0420.2006.00534.x Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios Guosheng Yin, Yisheng Li, and Yuan
More informationUser Guide Web-Based Portal v1.7
Escalation With Overdose Control User Guide Web-Based Portal v1.7 January 2017 Biostatistics and Bioinformatics Research Center Web-EWOC Development Team Concept, Overall Design and Coordination: Web Architecture
More informationFlexible early-phase design for combination therapies
Flexible early-phase design for combination therapies Nolan A. Wages, PhD Associate Professor Department of Public Health Sciences University of Virginia May 30, 2018 Nolan A. Wages, PhD (UVA) The 2nd
More informationStatistical Methods for Bayesian Adaptive Early-Phase Clinical Trial Designs
Statistical Methods for Bayesian Adaptive Early-Phase Clinical Trial Designs by Jin Zhang A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Biostatistics)
More informationarxiv: v1 [stat.me] 10 Jun 2017
AAA: Triple-adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose-finding trials arxiv:1706.03278v1 [stat.me] 10 Jun 2017 Jiaying Lyu Department of Biostatistics,
More informationAdaptive Designs for Identifying Optimal Biological Dose for Molecularly Targeted Agents
Adaptive Designs for Identifying Optimal Biological Dose for Molecularly Targeted Agents Yong Zang, J Jack Lee and Ying Yuan Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center,
More informationFriday, September 12th, :00-11:00 am New Research Building Auditorium Refreshments will be provided at 9:45am. Gang Han, Ph.D.
Friday, September 12th, 2014 10:00-11:00 am New Research Building Auditorium Gang Han, Ph.D. Associate Research Scientist in Public Health (Biostatistics) School of Public Health, Yale Center for Analytical
More informationNovel Methods for. Early Phase Clinical Trials
Novel Methods for Early Phase Clinical Trials Amy Louise Cotterill, B.Sc., M.Sc. Submitted for the degree of Doctor of Philosophy at Lancaster University. August 21, 2015 Novel Methods for Early Phase
More informationTranslational Update of Probability of Success in Drug Development
Translational Update of Probability of Success in Drug Development Francois Vandenhende, Ph.D. Chairman and Executive Consultant, ClinBAY Invited Lecturer, Institute of Statistics, UCL, Belgium francois@clinbay.com
More informationIncreasing Wireless Revenue with Service Differentiation
Increasing Wireless Revenue with Service Differentiation SIAMAK AYANI and JEAN WALRAND Department of Electrical Engineering and Computer Sciences University of California at Berkeley, Berkeley, CA 94720,
More informationAdaptive Model-Based Designs in Clinical Drug Development. Vlad Dragalin Global Biostatistics and Programming Wyeth Research
Adaptive Model-Based Designs in Clinical Drug Development Vlad Dragalin Global Biostatistics and Programming Wyeth Research 2007 Rutgers Biostatistics Day February 16, 2007 Outline Definition and general
More information3 Phases of Investigation
Part I: The scientific setting - December 30, 2009, 1 3 Phases of Investigation As discussed in Chapter 1, science is adversarial; scientists should consider all possible hypotheses, and only eliminate
More informationBAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS
The Annals of Applied Statistics 2011, Vol. 5, No. 2A, 924 942 DOI: 10.1214/10-AOAS433 Institute of Mathematical Statistics, 2011 BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED
More informationUnderstanding the FDA Guidance on Adaptive Designs: Historical, Legal and Statistical Perspectives
Understanding the FDA Guidance on Adaptive Designs: Historical, Legal and Statistical Perspectives Copyright c Qing Liu, Ph.D. qliu2@its.jnj.com Statistical Science Janssen R&D of Johnson & Johnson BASS
More informationExperience with Bayesian Clinical Trial Designs for Cardiac Medical Devices
Experience with Bayesian Clinical Trial Designs for Cardiac Medical Devices Andrew Mugglin Statistics Manager Cardiac Rhythm Management Clinical Research Medtronic, Inc. Acknowledgements with thanks to
More informationDisclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA
On multiplicity problems related to multiple endpoints of controlled clinical trials Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA JSM, Vancouver, August 2010 Disclaimer
More informationFDA S DRAFT GUIDANCE ON MULTIPLE ENDPOINTS IN CLINICAL TRIALS: OVERVIEW, RECEPTION AND NEXT STEPS. John Scott, Ph.D. FDA/CBER 5 October 2017
FDA S DRAFT GUIDANCE ON MULTIPLE ENDPOINTS IN CLINICAL TRIALS: OVERVIEW, RECEPTION AND NEXT STEPS John Scott, Ph.D. FDA/CBER 5 October 2017 Disclaimer 2 This presentation reflects the views of the author
More informationNovel Bayesian Adaptive Designs for Early Phase Oncology Clinical Trials
Novel Bayesian Adaptive Designs for Early Phase Oncology Clinical Trials A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Kristen M. Cunanan IN PARTIAL FULFILLMENT
More informationDaniel Sabanés Bové (presented by Giuseppe Palermo)
Model-based D/E designs: Current status and next steps Basel Biometrics Society Seminar, 26 June 2017 Daniel Sabanés Bové (presented by Giuseppe Palermo) Background of early phase clinical trials Main
More informationA Life-cycle Approach to Dose Finding Studies
A Life-cycle Approach to Dose Finding Studies Rajeshwari Sridhara, Ph.D. Director, Division of Biometrics V Center for Drug Evaluation and Research, USFDA This presentation reflects the views of the author
More informationUtility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Clinical Trials
Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Clinical Trials Peter F. Thall Department of Biostatistics University of Texas, M.D. Anderson Cancer
More informationModels for Computer-Aided Trial & Program Design
Models for Computer-Aided Trial & Program Design Terrence Blaschke, M.D. VP, Methodology and Science Pharsight Corporation & Professor of Medicine & Molecular Pharmacology Stanford University MODELS What
More informationExperience with Adaptive Dose-Ranging Studies in Early Clinical Development
Experience with Adaptive Dose-Ranging Studies in Early Clinical Development Judith Quinlan MSc Vice President Adaptive Trials Cytel Inc. judith.quinlan@cytel.com Thanks to members of the PhRMA Adaptive
More informationDose-Finding Designs for Early-Phase Clinical Trials and Outcome Dependent Sampling for Longitudinal Studies of Gene-Environment Interaction
Dose-Finding Designs for Early-Phase Clinical Trials and Outcome Dependent Sampling for Longitudinal Studies of Gene-Environment Interaction by Zhichao Sun A dissertation submitted in partial fulfillment
More informationBIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS CLINICAL PHASE Clinical Studies: Class of all scientific approaches to evaluate Disease Prevention,
More informationFacilitating Antibacterial Drug Development: Bayesian vs Frequentist Methods
Facilitating Antibacterial Drug Development: Bayesian vs Frequentist Methods Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington The Brookings Institution May 9, 2010 First:
More informationFit-for-purpose limits and Tolerance intervals: connecting the assay performance to the clinical trial
Fit-for-purpose limits and Tolerance intervals: connecting the assay performance to the clinical trial Astrid Jullion & Bruno Boulanger Exploratory Statistics Pharmacometrics Lou, living with epilepsy
More informationMeta-analysis of clinical dose response in a large drug development portfolio
Meta-analysis of clinical dose response in a large drug development portfolio N. Thomas 1, K. Sweeney, and V. Somayaji 1 Pfizer Inc 445 Eastern Point Road Groton, CT 06340 ASA-NJ, June 2014 Thomas, Sweeney,
More informationDecision Making in Basket Trials: A Hierarchical Weights Approach
Introduction Hierarchical Weights Discussion Decision Making in Basket Trials: A Hierarchical Weights Approach David Dejardin 1, Thomas Bengtsson 2, Ulrich Beyer 1, Daniel Sabanés Bové 1 and Paul Delmar
More informationUnit 14: Introduction to the Use of Bayesian Methods for Reliability Data
Unit 14: Introduction to the Use of Bayesian Methods for Reliability Data Ramón V. León Notes largely based on Statistical Methods for Reliability Data by W.Q. Meeker and L. A. Escobar, Wiley, 1998 and
More informationUnit 14: Introduction to the Use of Bayesian Methods for Reliability Data. Ramón V. León
Unit 14: Introduction to the Use of Bayesian Methods for Reliability Data Ramón V. León Notes largely based on Statistical Methods for Reliability Data by W.Q. Meeker and L. A. Escobar, Wiley, 1998 and
More informationUnderstanding the Continual Reassessment Method for Dose Finding Studies: An Overview for Non-Statisticians
Johns Hopkins University, Dept. of Biostatistics Working Papers 3-3-2005 Understanding the Continual Reassessment Method for Dose Finding Studies: An Overview for Non-Statisticians Elizabeth Garrett-Mayer
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS Steps to New Drug Discovery Get idea for drug target Develop a bioassay Screen chemical compounds
More informationPharmaSUG 2017 Paper 47
PharmaSUG 2017 Paper 47 Visualization & interactive application in design and analysis by using R Shiny Baoyue LI, Eli Lilly & Company, Shanghai, China Boyao SHAN, Eli Lilly & Company, Shanghai, China
More informationIntroduction to Quantitative Genomics / Genetics
Introduction to Quantitative Genomics / Genetics BTRY 7210: Topics in Quantitative Genomics and Genetics September 10, 2008 Jason G. Mezey Outline History and Intuition. Statistical Framework. Current
More informationSIMULATION EXPERIMENT PLATFORM FOR EVALUATING CLINICAL TRIAL DESIGNS, WITH APPLICATIONS TO PHASE I DOSE-FINDING CLINICAL TRIALS.
SIMULATION EXPERIMENT PLATFORM FOR EVALUATING CLINICAL TRIAL DESIGNS, WITH APPLICATIONS TO PHASE I DOSE-FINDING CLINICAL TRIALS by Yuanyuan Wang BS, University of Science and Technology of China, China,
More informationMoving Forward. Adaptive Eligibility Criteria, Alternate Trial Designs, and Subgroup Analysis. Elizabeth Garrett-Mayer, PhD
Moving Forward Adaptive Eligibility Criteria, Alternate Trial Designs, and Subgroup Analysis Elizabeth Garrett-Mayer, PhD Eligibility Trade-offs Broad eligibility Pros: Heterogeneous group Can generalize
More informationPART I. Clinical Trials COPYRIGHTED MATERIAL
PART I Clinical Trials COPYRIGHTED MATERIAL CHAPTER 1 Phase I Clinical Trials Anastasia Ivanova Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina Nancy Flournoy Department
More information31 Mar Two Bayesian designs for first-in-human trials in cancer. Nedjad Losic March 31, 2017
Two Bayesian designs for first-in-human trials in cancer Nedjad Losic March 31, 2017 2 1 Agenda Two Bayesian designs for first-inhuman trials in cancer Quick intro to first-in-human trials in cancer Continual
More informationParametric non-mixture cure models for schedule finding of therapeutic agents
Appl. Statist. (2009) 58, Part 2, pp. 225 236 Parametric non-mixture cure models for schedule finding of therapeutic agents Changying A. Liu and Thomas M. Braun University of Michigan, Ann Arbor, USA [Received
More informationModeling and Simulation for Dose Selection using Adaptive Designs
Modeling and Simulation for Dose Selection using Adaptive Designs Nitin Patel Chairman and C.T.O. Cytel, Inc. Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationMeta-analysis of clinical dose response in a large drug development portfolio
Meta-analysis of clinical dose response in a large drug development portfolio N. Thomas 1, K. Sweeney, and V. Somayaji 1 Pfizer Inc 445 Eastern Point Road Groton, CT 06340 BASS, 2013 Thomas, Sweeney, Somayaji
More informationEvaluation of Diagnostic Agents: a SAS Macro for Sample Size Estimation Using Exact Methods
Paper ST02 Evaluation of Diagnostic Agents: a SAS Macro for Sample Size Estimation Using Exact Methods Stefano Vezzoli, CROS NT, Verona, Italy ABSTRACT In a study assessing the diagnostic performance of
More informationA Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation
Research Article A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation Chunyan Cai a, Suyu Liu b and Ying Yuan b Interim monitoring is routinely conducted in
More informationShort Course: Adaptive Clinical Trials
Short Course: Adaptive Clinical Trials Presented at the 2 Annual Meeting of the Society for Clinical Trials Vancouver, Canada Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical
More informationThe Integrated Web Portal for Escalation with Overdose Control (EWOC)
Send Orders of Reprints at reprints@benthamscience.net 18 The Open Medical Informatics Journal, 2013, 7, 18-23 Open Access The Integrated Web Portal for Escalation with Overdose Control (EWOC) Haibin Wang
More informationPackage pocrm. R topics documented: March 3, 2018
Package pocrm March 3, 2018 Type Package Title Dose Finding in Drug Combination Phase I Trials Using PO-CRM Version 0.11 Date 2018-03-02 Author Nolan A. Wages Maintainer ``Varhegyi, Nikole E. (nev4g)''
More informationGuiding dose escalation studies in Phase 1 with unblinded modeling
Guiding dose escalation studies in Phase 1 with unblinded modeling Andreas Krause Lead Scientist Modeling & Simulation Andreas.Krause@idorsia.com Basel Biometrics Section (BBS) Seminar: Innovative model-based
More informationPackage ph2bayes. February 26, 2018
Package ph2bayes February 26, 2018 Type Package Title Bayesian Single-Arm Phase II Designs Version 0.0.2 An implementation of Bayesian singlearm phase II design methods for binary outcome based on posterior
More informationA Bayesian Adaptive Design for Multi-Dose, Randomized, Placebo-Controlled Phase I/II
A Bayesian Adaptive Design for Multi-Dose, Randomized, Placebo-Controlled Phase I/II Trials Fang Xie, 1 Yuan Ji, 2 Lothar Tremmel 3 1: Cephalon, Inc., Frazer, PA, USA 2: The University of Texas M. D. Anderson
More informationEvaluating dose-response under model uncertainty using several nested models
Evaluating dose-response under model uncertainty using several nested models Corine Baayen 1,2, Philip Hougaard 1 & Christian Pipper 2 1 H. Lundbeck A/S 2 University of Copenhagen October 2014 Baayen,
More informationDiagnostic Screening Without Cutoffs
Diagnostic Screening Without Cutoffs Wesley O. Johnson Young-Ku Choi Department of Statistics and Mark C. Thurmond Department of Medicine and Epidemiology University of California, Davis Introduction Standard
More informationBayesian Monitoring of A Longitudinal Clinical Trial Using R2WinBUGS
Bayesian Monitoring of A Longitudinal Clinical Trial Using R2WinBUGS Annie Wang, PhD; Narinder Nangia, PhD Abbott Laboratories The R User Conference 2010, user! 2010 Gaithersburg, Maryland, USA Outline
More informationInteractive Software Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS TM) for Cancer Phase I Clinical Trials
Interactive Software Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS TM) for Cancer Phase I Clinical Trials Zhengjia Chen, Emory University Zhibo Wang, Emory University Haibin Wang,
More informationTHREE LEVEL HIERARCHICAL BAYESIAN ESTIMATION IN CONJOINT PROCESS
Please cite this article as: Paweł Kopciuszewski, Three level hierarchical Bayesian estimation in conjoint process, Scientific Research of the Institute of Mathematics and Computer Science, 2006, Volume
More informationA new approach to designing phase I-II cancer trials for cytotoxic chemotherapies
Research Article Received 9 October 2012, Accepted 6 February 2014 Published online 27 February 2014 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.6124 A new approach to designing phase
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Combination Chemotherapy: DESIGNING CLINICAL RESEARCH Use of a combination of two therapeutics, especially drug-drug combination (called combination
More informationExtensive Experimental Validation of a Personalized Approach for Coping with Unfair Ratings in Reputation Systems
Extensive Experimental Validation of a Personalized Approach for Coping with Unfair Ratings in Reputation Systems Nanyang Technological University, School of Computer Engineering, zhangj@ntu.edu.sg Received
More informationFormalizing Study Design & Writing Your Protocol. Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care
TWIST: Formalizing Study Design & Writing Your Protocol Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care Presented by the Joint Clinical Trials Office/Quality Assurance Unit
More informationSymmetric Information Benchmark Begin by setting up a comparison situation, where there is no information asymmetry. Notation:
ECO 37 Economics of Uncertainty Fall Term 009 Notes for Lectures 7. Job Market Signaling In this market, the potential employee s innate skill or productive capability on the job matters to an employer
More information